Study of GZR102, GZR4, and GZR18 injections in overweight adults
Part of Hormones & metabolism clinical trials.
This trial tests a new injection (GZR102) compared to two other injections (GZR4 and GZR18) in overweight adults. The goal is to see how well the body processes each drug and their effects. It may help researchers find a better treatment for weight management.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- Your weight is at least 60 kg (about 132 lbs) and your BMI is between 24 and 28.
- You are not planning to become pregnant or donate sperm for at least 8 weeks after the study, and you agree to use effective birth control.
- You have no history of drug or alcohol abuse, and you do not smoke heavily (or can stop smoking during the study).
- You have not had cancer, pancreatic issues, major surgery, or blood donation in the past few months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a new injectable weight loss drug affects the way the body processes metformin, a common diabetes medication. It is for Chinese adults who are overweight or obese.
This study tests a new once-daily insulin (GZR4) against an approved insulin (degludec) in people with type 2 diabetes to see how well it controls blood sugar. You may qualify if you are already using a stable dose of background insulin.
This trial tests how a single injection of a new drug called GZR4 is absorbed when given at different injection sites (like the belly or thigh) in healthy men. It helps researchers understand how the drug works in the body before testing it in people with diabetes.
This trial tests how a new drug called GZR18 (given as an injection) affects the body in people with different levels of kidney function. It aims to find the right dose and check for side effects, which could help guide treatment for people with kidney issues.
This study tests a new drug called GZR18 to see how it works in people with different levels of liver function. It aims to help find the right dose and check safety.
This study is for people who finished a previous weight loss trial and want to continue treatment with an injectable medication GZR18. It tests how well the medicine works over a longer period.
Hear when a new Type 2 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.